Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Axial
Bone repair system reduces pain after surgery and brings better recovery

Axial Orthopaedics Inc. revolutionizes trauma treatment with their innovative intramedullary nailing system. Current systems often lead to bone misalignment and joint pain, blocking post-procedural recovery. Axial Orthopaedics's modular system offers greater flexibility in bone alignment and healing. This system not only addresses postoperative pain but also reduces complications. Its intra-operative modularity and rotational capabilities allow surgeons to achieve better fracture fixation and improved outcomes, filling a crucial gap in current technology.

Active
🇺🇸 United States of America
Axial
Artifex
Off the shelf vascular graft alternative

ArtiFex tackles a solution for coronary and peripheral bypass surgeries. Traditional grafts from the great saphenous vein face issues like rapid degeneration, leading to complications. With millions of bypass surgeries conducted annually and a billion-dollar market for vascular grafts, there's a clear need for improvement. ArtiFex's innovative vascular graft, made of cobalt-chrome and cellulose promotes tissue regeneration, strength, and ensures blood flow without causing clotting or immune reactions.

Active
🇦🇹 Austria
Artifex
Startric
Revolutionizing tricuspid valve repair with minimally invasive solutions

StarTric, created by cardiovascular experts, developed a new, less invasive device to fix a serious heart valve problem, Tricuspid Regurgitation (TR). Addressing Tricuspid Regurgitation (TR), a severe condition with high mortality rates, StarTric's device offers a safer alternative to open-heart surgery. The technology can be implanted via a transfemoral catheter, combining the safety of minimally invasive methods with the proven efficacy of the Clover technique, aiming to provide effective treatment to millions of TR patients worldwide who currently lack suitable options.

Active
🇮🇹 Italy
Startric
MLA Diagnostics
Personalised measurement of melanoma malignancy

MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.

Active
🇳🇱 Netherlands
MLA Diagnostics
Arne
Improving urgent neonatal care delivery with AR and AI

Arne enhances urgent neonatal care by using augmented reality and artificial intelligence to provide real-time clinical decision support. In stressful situations, doctors can miss critical protocol steps, but Arne’s smart software projects recommends actions directly into the doctor's field of vision, reducing errors and improving patient outcomes. This innovative tool ensures every newborn receives optimal care, while empowering neonatologists.

Active
🇳🇱 Netherlands
Arne
Neurolieve Biosciences
Developing Fc2-13 GalR2, an innovative bioengineered protein targeting neuropathic pain.

Neurolieve Biosciences, a pre-clinical stage company, is developing Fc2-13 GalR2, an innovative bioengineered protein (FC fusion protein) targeting neuropathic pain. Peripheral Neuropathy, a debilitating condition affecting millions, damages the peripheral nervous system, causing severe discomfort and lowering quality of life. The fusion protein reduces peripheral neuron excitability, providing pain relief. After successful in vitro and in vivo validations, the company is advancing towards GLP toxicology studies completion.

Active
🇬🇧 United Kingdom
Neurolieve Biosciences
Angiogenesis Analytics
Detecting, locating, and characterizing prostate cancer using ultrasound

Angiogenesis Analytics, offers an ultrasound-based solution for detecting, localizing, and characterizing prostate cancer. Each year, over 1.5 million men undergo invasive biopsies with risks of infection, false negatives, and overtreatment. Angiogenesis Analytics eliminates these issues by providing a non-invasive, accurate, and cost-effective alternative, improving patient comfort and outcomes. With an estimated market value of USD 450 million annually, Angiogenesis Analytics addresses a significant global need for better prostate cancer diagnostics.

Active
🇳🇱 Netherlands
Angiogenesis Analytics
Nilocas
A cardiac device for the detection of coronary artery disease

Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

Active
🇬🇧 United Kingdom
Nilocas

Our impact

15
Countries active in
2.4M
Patients impacted
20-25
Ventures built annually
70+
Active ventures in our portfolio
80+
Healthcare experts
€160M+
Raised by NLC ventures

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director